register

News & Trends - Pharmaceuticals

Roche’s adjuvant treatment PBS listed in early breast cancer

Health Industry Hub | April 1, 2020 |

Effective 1st April 2020, Roche’s Kadcyla is listed on the Pharmaceutical Benefits Scheme (PBS), for the adjuvant treatment of patients with HER2-positive early breast cancer (eBC) who have residual invasive disease after neoadjuvant taxane and trastuzumab-based treatment.

In the adjuvant setting, Kadcyla was found to have reduced disease recurrence by 50% (HR=0.50, 95% CI 0.39-0.64; p<0.001) in patients with HER2-positive early breast cancer, who had residual invasive disease following neoadjuvant taxane and trastuzumab-based treatment.

Associate Professor Elisabeth Elder, specialist breast surgeon and head of research at the Westmead Breast Cancer Institute said “As a surgeon and a member of the multidisciplinary team, the shared goal is to provide the patient with optimal treatment options and ultimately maximise success in eliminating the disease. Neoadjuvant therapy is a key part of ensuring that patients are not losing further treatment options like adjuvant Kadcyla.”

HCP engagement during COVID-19. Health Industry Hub combines expertise in target audience insights, delivering digital health content and measuring engagement with 20+ years industry experience. Created by industry for industry. Contact us.

Australian guidelines recommend that treatment of early breast cancer be provided by a multidisciplinary team, consisting of at least a surgeon, medical oncologist, radiation oncologist, radiologist and nurse, to ensure optimal patient outcomes.

As surgeons are often the first point of contact for breast cancer patients along the treatment journey, they play an important role in identifying patients who would benefit from neoadjuvant therapy.

Breast surgeon and Vice President of BreastSurgANZ, Dr. Melanie Walker further highlighted the advantages of neoadjuvant treatment in helping to improve patient outcomes by offering additional treatment options in the adjuvant setting.

“Neoadjuvant therapy can act as an in vivo model of disease that is important prognostically for assessing tumour response to treatment and allowing adaptation in post-surgery treatment to maximise patient outcomes. It is no longer simply a tool for improving surgical outcomes but a crucial part of the optimal treatment pathway,” said Dr. Walker.

According to international guidelines, neoadjuvant treatment should be considered for all appropriate patients, especially those with HER2-positive and triple-negative breast cancer, as part of optimal treatment planning.

According to medical oncologist, Dr Richard de Boer, from St Vincent’s Private Hospital Melbourne, “The changing algorithm of treatment in early breast cancer means we can offer patients with HER2-positive breast cancer better treatment options that can reduce the risk of disease recurrence – which is a significant cause of anxiety for breast cancer patients.”

Register FREE and join 20,000+ industry professionals receiving the latest industry news and engaging content from Health Industry Hub; the ONLY one-stop-hub connecting Australia’s Pharma, MedTech and Biotech industry professionals.

Breast cancer is the most common cancer affecting Australian women, with 1 in 7 women being diagnosed with breast cancer by the age of 85.8. In 2020, it is estimated that around 20,000 women and 170 men will be diagnosed with breast cancer.

HER2-positive cancer accounts for approximately 15-20% of breast cancer cases and is associated with a more aggressive form of the disease.

Roche Australia Managing Director Stuart Knight said “I congratulate the Federal Government on expediting the PBS listing of Kadcyla. Roche has a long heritage of innovation in breast cancer cancer, and I’m delighted that eligible patients now have an additional option for the adjuvant treatment of HER2-positive early breast cancer.”

You may also like MSD, Novartis and more unite alongside Gates Foundation in the flight against COVID-19


News & Trends - MedTech & Diagnostics

Medtronic partners with local researchers in stroke trial

Medtronic partners with local researchers in stroke trial

Health Industry Hub | March 1, 2024 |

MedTech & Diagnostics News: Endovascular thrombectomy has been shown to be more effective in reducing disability than medical therapy alone […]

More


News & Trends - Pharmaceuticals

Health Ministers reflect on the reforms and complexities facing the healthcare system

Health Ministers reflect on the reforms and complexities facing the healthcare system

Health Industry Hub | March 1, 2024 |

Pharma News: Mark Butler MP, Federal Minister for Health, and Senator Anne Ruston, Shadow Minister for Health, reflected on the […]

More


News & Trends - Pharmaceuticals

Gilead seeks funding of CAR T-cell therapy in follicular lymphoma

Gilead seeks funding of CAR T-cell therapy in follicular lymphoma

Health Industry Hub | March 1, 2024 |

Pharma News: Gilead has applied to the Medical Services Advisory Committee (MSAC) for funding of its cutting-edge CAR T-cell therapy, […]

More


News & Trends - MedTech & Diagnostics

Should private insurers face scrutiny for soaring profits while patients foot the bill? MTAA, Private Healthcare Australia

Should private health insurers face scrutiny for soaring profits while patients foot the bill?

Health Industry Hub | March 1, 2024 |

MedTech & Diagnostics News: In a clash of interests, the Medical Technology Association of Australia (MTAA) has once again urged […]

More


This content is copyright protected. Please subscribe to gain access.